ABBOTT INDIA LTD.

Abbott India Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and is in preparation for the declaration of the company's unaudited financial results for the quarter ending September 30, 2026. The trading window will be shut from October 1, 2026, and will reopen 48 hours after the financial results are officially declared. The company secretary, Sangeeta Shetty, has communicated this information.

Abbott India Limited announced its unaudited financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors at a meeting held on August 12, 2026. The company's financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and comply with SEBI Listing Regulations. The financial results have undergone a limited review by the statutory auditors, Walker Chandiok & Co. LLP, with no qualifications noted. The company operates in a single segment, Pharmaceuticals.

Abbott India's standalone Q1 FY27 (quarter ended June 30, 2026) print was a margin-led beat: revenue from operations grew a modest 4.3% YoY to ₹1,813.68 Cr (up 6.1% QoQ from ₹1,709.51 Cr), while profit after tax rose a sharper 17.1% YoY to ₹428.52 Cr (up 8.5% QoQ from ₹394.93 Cr), with EPS at ₹201.65 versus ₹172.17 a year ago. No exceptional or one-off items are visible in either the current or comparison periods, so the growth is organic — there is no raw-vs-adjusted split to make here. The gap between top-line and bottom-line growth is entirely a margin story. EBITDA-level operating margin (PBT + finance costs + depreciation, less other income, over revenue) expanded to 28.81% from 25.63% a year ago (+318 bps) and 28.13% last quarter (+68 bps); net margin on total income rose to 22.69% from 20.20% YoY (+249 bps). Cost of materials consumed fell to ₹150.63 Cr from ₹146.18 Cr a year ago as a share of a larger revenue base, and employee benefits expense actually declined YoY to ₹175.24 Cr from ₹168.01 Cr's prior-year base growing slower than revenue, while the tax rate held steady at 25.1% of PBT versus 25.7% a year ago — none of these individually stand out as one-offs, suggesting genuine operating leverage rather than a cost-line anomaly. We have no prior guidance or concall commentary on record for this company to check the print against, and management's press release/results commentary was not available at extraction time, so neither can be graded here. A web search for Street consensus on this quarter turned up no specific analyst estimates for Abbott India's Q1 FY27 PAT or revenue, so the print cannot be benchmarked against consensus either — vsStreet is marked unknown rather than guessed. Alongside the results, the board also approved a leadership transition: Sudarshan Jain succeeds Munir Shaikh as Chairman effective August 13, 2026, a governance change that is unrelated to the quarter's numbers but was disclosed in the same filing. Going into Q2 FY27, the key question is whether the ~29% OPM level holds as a new run-rate or reverts toward the 25-26% band seen a year ago, and whether revenue growth — running below double digits for two straight quarters — reaccelerates.

Abbott India Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item for this meeting is to consider and approve the company's unaudited financial results for the quarter ended June 30, 2026. In line with SEBI regulations, the trading window for the company's shares will remain closed from July 1, 2026, to August 14, 2026, inclusive, to prevent insider trading.

Abbott India Ltd has communicated the web link for its Annual Report for the financial year 2025-26. This communication is directed towards members whose email addresses are not registered with the company, RTA, or Depository Participants, as per SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The Annual Report is also available on the websites of BSE Limited and NSDL. This ensures all shareholders have access to the company's annual financial information.

Abbott India Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as required by SEBI regulations. The report, which includes an Independent Assurance Statement from DNV Business Assurance India Private Limited, details the company's performance across environmental, social, and governance (ESG) parameters. Key disclosures cover corporate identity, registered and corporate office details, financial year reporting period, stock exchange listings, paid-up capital, and contact information for BRSR queries. The report also outlines the company's business activities, products, operational locations, markets served (including exports), customer types, and employee statistics. Abbott India emphasizes its commitment to an inclusive workplace and has introduced initiatives like the disABILITY Network.

Abbott India Limited has issued a notice for its 82nd Annual General Meeting (AGM) scheduled to be held on August 13, 2026, through Video Conference/Other Audio-Visual Means. The meeting will cover ordinary business including the adoption of audited financial statements for FY 2025-26, declaration of a final dividend of ₹525 per share and a special dividend of ₹131 per share, and the retirement/re-appointment of directors Mr. Munir Shaikh and Mr. Kaiyomarz Marfatia. Special business includes the ratification of remuneration for Cost Auditors, M/s. Kishore Bhatia & Associates, for FY 2026-27, amounting to ₹0.09 Crores plus applicable taxes.

Abbott India Ltd has released its Annual Report for the financial year 2025-26, along with the notice for its 82nd Annual General Meeting (AGM). The AGM is scheduled for August 13, 2026, to be held via Video Conference/Other Audio-Visual Means. The report details the company's performance, business model, and statutory information. A final dividend of ₹525 and a special dividend of ₹131 per equity share, recommended by the Board, will be paid if approved by shareholders. The cut-off date for voting eligibility is August 6, 2026, and the dividend record date is July 24, 2026.

Abbott India Limited has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be closed effective Wednesday, July 1, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. This is a standard regulatory procedure to prevent potential insider trading during sensitive financial reporting periods.

Abbott India has issued a communication to its shareholders regarding Tax Deduction at Source (TDS) on dividends. The company will deduct TDS at prescribed rates based on shareholder status and PAN verification, as per the Income Tax Act, 2025. Shareholders are urged to update their PAN, bank details, and residential status by July 24, 2026, to comply with TDS provisions. The recommended final dividend is INR 525 and special dividend is INR 131 per share, subject to AGM approval.